# OnCo record kymathera (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kymathera/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kymathera" ;
  schema:name "KymaThera"@en ;
  schema:description "KymaThera is developing K-1728, a pill that blocks the faulty forms of the PI3K-alpha enzyme found in many hormone receptor-positive breast cancers while largely sparing the normal enzyme. It expected to start its first human trial in late 2026."@en ;
  schema:url <https://onco.cc/companies/kymathera/>, <https://kymathera.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://kymathera.com/>, <https://www.prnewswire.com/news-releases/kymathera-announces-80-million-series-b-financing-to-advance-k-1728-a-next-generation-pan-mutant-selective-pi3k-inhibitor-for-cancer-and-vascular-malformations-302899716.html> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/> .